Walleye Capital’s MaxCyte MXCT Stock Holding History

Walleye Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-110,891	Closed	-$461K	–	4810
2024 Q4	$461K	Buy	+110,891	New	+$419K	﹤0.01%	3056

Other funds holding MXCT

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Walleye Capital's MXCT Position: Q1 2025 in Review

Walleye Capital sold out of MaxCyte (MXCT) in Q1 2025, closing a stake of 110,891 shares — an estimated $461K sold.

Walleye Capital first reported a position in MXCT in Q4 2024 and held it in 1 quarter. The position peaked at $461K in Q4 2024. 115 funds tracked by Wall St. Rank hold MXCT as of Q1 2025.

Walleye Capital reported no remaining MaxCyte position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 110,891 MaxCyte shares in Q1 2025, an estimated $461K.
Walleye Capital first reported a position in MaxCyte in Q4 2024 and held it in 1 quarter.
Walleye Capital's MaxCyte position peaked at $461K in Q4 2024.
115 funds tracked by Wall St. Rank held MaxCyte as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.